Headline: Lilly Gets Fourth FDA Approval for ALIMTA
A spokesperson for Eli Lilly and Co. (LLY), one of the leading US pharmaceutical manufacturers, released a statement last week that the US Food and Drug Administration (FDA) has granted a fourth approval for the cancer drug ALIMTA to be used as an upkeep therapy for locally advanced or metastatic non-small cell lung cancer (NSCLC). […]
Headline: Lilly Gets Fourth FDA Approval for ALIMTA Read More »